Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

Conditions:   Superficial, Palpable, Unresectable/Metastatic Solid Tumour;   Metastatic Colorectal Cancer;   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: AGI-134;   Drug: AGI-134 + Pembrolizumab
Sponsor:   Agalimmune Ltd.
Not yet recruiting

https://ift.tt/2uPn61K